As with other CMT blood biomarker studies, we found that circulating NF-L (76–79) and Gdf15 (80, 81) levels, associated with axonal degeneration, were significantly ameliorated after early treatment of CMT1A mice with AAV9-miR871 (NF-L: 321.37 ± 51.68 pg/mL; Gdf15: 56.25 ± 14.84 pg/mL) compared with their AAV9-miRLacZ vector–treated littermates (540.65 ± 134.49 pg/mL; Gdf15: 81.93 ± 23.12 pg/mL) (Figure 3, Q and R). Here, GDF15 is linked to Charcot-Marie-Tooth disease type 1A.